Clinical Trial Update: Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating apatinib plus docetaxel in advanced non-squamous non-small cell lung cancer (NSCLC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Apatinib (apatinib)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Affiliated Hospital of North Sichuan Medical College | Conditions: NSCLC | Phase 2 | Status: UNKNOWN